Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Wide distribution of CVD-free life-years gained with GLP-1RA

5' education - Mar. 21, 2022 - Jan Westerink, MD, PhD

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Rethinking responsibilities in the prevention and management of cardiometabolic disease

10' education - Dec. 7, 2021 - Prof. Stephan Jacob, MD

What is the effect of low-dose aspirin on dementia risk in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

Interpreting findings of studies on a non-steroidal MRA in T2DM and CKD

10' education - Nov. 9, 2021 - Prof. George Bakris, MD, prof. Betram Pitt, MD and prof. Rajiv Agarwal, MD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME
5 Things a cardiologist needs to know about GLP-1RA

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD - Online CME

Primary endpoint met in phase III trial with SGLT2i in HFpEF

News - May 9, 2022

A significant reduction in the primary composite endpoint of CV death or worsening HF was reached with dapagliflozin in HF patients with LVEF >40% in the DELIVER phase III trial.

Influence of MRA use on benefit of SGLT2i in HFpEF

Literature - Apr. 28, 2022 - Ferreira JP, et al. - J Am Coll Cardiol. 2022

A secondary analysis of the EMPEROR-Preserved shows that empagliflozin reduces the primary outcome regardless of background mineralocorticoid receptor antagonists (MRA) therapy. Reduction of total HF hospitalization was more pronounced in MRA nonusers.

Omega-3 fatty acids reduce HF hospitalization in T2DM patients

Literature - Apr. 20, 2022 - Djoussé L, et al. - JACC Heart Fail. 2022

Omega-3 fatty acids have a beneficial effect on the number of HF hospitalizations in people with T2DM, especially in black people with T2DM.

Electronic health record alert improves guideline-directed therapy prescription for HFrEF

News - Apr. 12, 2022

ACC 2022 A randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.

Phase 3 CV outcomes study with pemafibrate stopped early

News - Apr. 11, 2022

The PROMINENT study, which investigated whether pemafibrate could reduce CV outcomes by reducing triglycerides in patients with T2DM, will be stopped early.

CV and kidney benefits of nonsteroidal MRA irrespective of ASCVD history

News - Apr. 11, 2022

ACC 2022 A subanalysis of FIDELITY shows that the nonsteroidal MRA finerenone resulted in CV and kidney benefits in both primary and secondary prevention groups in a patient population with CKD and T2DM.

SGLT2i improves symptoms, physical function and quality of life in acute HF

News - Apr. 5, 2022

ACC 2022 This analysis showed that treatment with empagliflozin in patients with acute HF resulted in clinical benefit, regardless of symptomatic impairment at baseline, and improved symptoms, physical function and quality of life.

Wide distribution of CVD-free life-years gained with GLP-1RA

5' education - Mar. 21, 2022 - Jan Westerink, MD, PhD
Translating trial results and recommendations from guidelines to individual patients can be challenging. Jan Westerink shares the findings of a study on the calculation of individual absolute benefit with semaglutide in patients with T2DM.

Translating trial results and recommendations from guidelines to individual patients can be challenging. Jan Westerink shares the findings of a study on the calculation of individual absolute benefit with semaglutide in patients with T2DM.

Estimated life-years free of CVD with GLP-1RA in patients with T2DM

Literature - Mar. 21, 2022 - Westerink J, et al. - Diabetes Care 2022

Using the DIAL model and pooled data from SUSTAIN 6 and PIONEER 6, a study shows that treatment with semaglutide is associated with a wide distribution in the gain in life-years free of CVD, that was dependent on baseline CVD risk and age at treatment initiation.

Early stop of phase III trial evaluating SGLT2 inhibitor in CKD

News - Mar. 21, 2022

The Independent Data Monitoring Committee of the EMPA-KIDNEY trial has recommended to stop the trial early due to positive efficacy. The EMPA-KIDNEY trial evaluates the effect of empagliflozin in adults with CKD.

European Commission approves SGLT2i in chronic HF regardless of ejection fraction

News - Mar. 8, 2022

Empagliflozin has received approval from the European Commission for the treatment of symptomatic chronic HF across the full spectrum of LVEF.

Combination of ARNI, BB, MRA, and SGLT2i most effective in reducing outcomes in HFrEF

Literature - Mar. 7, 2022 - Tromp J et al. - JACC Heart Fail. 2022

This meta-analysis estimated and compared the effects of combinations of different pharmacological therapies for HFrEF.